MoonLake Immunotherapeutics (MLTX)
40.86
+0.17
(+0.42%)
USD |
NASDAQ |
May 16, 16:00
40.85
-0.01
(-0.02%)
After-Hours: 20:00
MoonLake Immunotherapeutics Cash from Operations (Quarterly): -14.95M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -14.95M |
| December 31, 2023 | -12.34M |
| September 30, 2023 | -9.251M |
| June 30, 2023 | -12.16M |
| March 31, 2023 | -9.024M |
| Date | Value |
|---|---|
| December 31, 2022 | -11.60M |
| September 30, 2022 | -9.352M |
| June 30, 2022 | -20.76M |
| March 31, 2022 | -14.19M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-20.76M
Minimum
Jun 2022
-9.024M
Maximum
Mar 2023
-12.62M
Average
-12.16M
Median
Jun 2023
Cash from Operations (Quarterly) Benchmarks
| Qiagen NV | 133.08M |
| LENZ Therapeutics Inc | -23.94M |
| AC Immune SA | 1.172M |
| CRISPR Therapeutics AG | 109.75M |
| Addex Therapeutics Ltd | -0.5563M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -28.80M |
| Cash from Financing (Quarterly) | 50.98M |
| Free Cash Flow | -48.91M |
| Free Cash Flow Per Share (Quarterly) | -0.242 |
| Free Cash Flow Yield | -2.18% |